by stefan | Nov 1, 2021 | Blog, Geen categorie
Oss, The Netherlands, November 1st, 2021 Immagene B.V. today announces it has raised a seed financing round to advance its next-generation precision Immuno-Oncology (IO) therapeutics. BOM Brabant Ventures joined as a new investor with additional support from...
by stefan | Oct 28, 2021 | Blog, Geen categorie
– Expanded investor syndicate strengthens the company’s financial position and investor base ROTTERDAM, October 28, 2021 – Pan Cancer T B.V., a biotech spin-off from the Erasmus MC dedicated to the discovery and development of novel TCR-T therapies against...
by stefan | Feb 8, 2021 | Blog
Onco-immunology Company Pan Cancer T Launched as Spin-off from Erasmus Medical Center – Dutch biotech company developing first-in-class T-cell Receptor (TCR) T-cell therapies – Seed investment by Swanbridge Capital and Van Herk Ventures with support from...
by stefan | Nov 24, 2020 | Blog
Ghent, Belgium / Rotterdam, The Netherlands / Miami, FL, USA – November 24, 2020 Allero Therapeutics BV, a Belgian-Dutch oromucosal immunotherapy company, and Abbreos Inc., a US- based IND-stage company focused on developing treatments that dampen hyperactive...
by stefan | Sep 29, 2020 | Blog
Official launch of Immagene: Dutch company developing next-generation immuno-oncology therapeutics Immagene B.V. launched this month as a private biotech company developing next-generation precision immuno-oncology (IO) treatments. The company based in...
by stefan | Oct 30, 2019 | Blog
3 October 2019 Life sciences seed capital fund Curie Capital today announced the closing of a seed investment in Allero Therapeutics, a biopharmaceutical company focused on the development of novel immunotherapies. The company has developed a proprietary platform...
Recent Comments